bioSeedin’s Post

Amid global economic uncertainties and challenges in biotech, the APAC region stands tall as a resilient and promising market for clinical trials. Whether you're an emerging biopharma innovator or technology provider, our 3rd Clinical Trials Festival Asia (CTFA) 2025 in Singapore connects you with world-class industry leaders in Biologics, Cell & Gene Therapy, and Vaccines. CTFA 2025 will be held on 12th-13th March under one roof with: ⚗️12th Biologics Manufacturing Asia 🚚 9th Biologistics World Asia 🌐 2nd Biologics Digitalization and AI World 💉Antibody-Drug Conjugate Asia Congress Expect insights from 300+ attendees, 150+ companies, and 30+ experts, with opportunities to engage top leaders, explore tailored solutions, and network at the Asia-Pacific Biopharma Excellence Awards Gala. 🔗 Discover who’s attending and get insights—Download the 2024 attendee list and post-event report! https://lnkd.in/gCBhYSXG #ClinicalTrials #Biopharma #CRO #CellandGeneTherapy #APACInnovation #Biologics #Vaccines

Thoughts on this? >> Bluebird bio stock gains after Q1 2024 results (NASDAQ:BLUE) - Seeking Alpha >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharma #pharmaceutical

By 2027, the rise of biologics and personalized therapies will drive a transformation in aseptic manufacturing, emphasizing the need for adaptable, multi-product facilities and advanced aseptic processes to ensure safety and efficiency. Read more ⬇️

Hello Connection📢 I am thrilled to share that I had the privilege of attending the 68th SPSR #International_Webinar titled #Solid_Lipid_Nanoparticulate_Systems (SLNs): A Latest Approach for Delivering Drugs," organized by the Society of Pharmaceutical Sciences and Research (SPSR) on October 6, 2024. Solid Lipid Nanoparticles (SLNs) represent a cutting-edge colloidal drug delivery system. It offer a revolutionary method for targeted drug delivery, combining stability, biocompatibility, and versatility in transporting a variety of therapeutic agents. Key Highlights of SLNs: Composition: SLNs consist of a solid lipid core stabilized with emulsifiers and dispersed in an aqueous medium. They are solid at both room and body temperature. Advantages: • High physical stability • Protecting drugs from degradation. • Biocompatibility • Versatility • Economical and scalable for large-scale manufacturing. Applications: • Used for delivering antiparasitic and anthelmintic drugs. • Explored for ocular drug delivery and gene therapy. The webinar was a great opportunity to learn more about the latest innovations in drug delivery systems using SLNs. I am grateful for the insightful presentations and discussions that have further enhanced my knowledge in this exciting area of pharmaceutical sciences. A heartfelt thank you to SPSR and Mrs. Monika Sabharwal for organizing such an informative and engaging session! I look forward to applying the valuable insights gained into my future research and professional endeavors. #PharmaInnovation #DrugDelivery #SLNs #Nanotechnology #PharmaceuticalResearch #SPSR #PharmaceuticalSciences #Nanoparticles #SPSR #DrugDevelopment #Pharmawebinar #Solid_Lipid_Nanoparticulate_Systems #Biotechnology #Nanomedicine #TargetedTherapy #PharmaTrends #ClinicalResearch #AdvancedDrugDelivery

CDMO - Cell and Gene Therapy (CGT) Represents the Next Phase of Growth ➡ The CDMO sector is still young, somewhat consolidated now, and growing in mid-to-high single digits ➡ We see this trend to continue driven by biopharma industry’s rising appetite to outsource production, in the backdrop of an increasingly complex manufacturing process, the need from relatively smaller biotechs for an experienced manufacturing partner to scale quickly while avoiding large capital outlays   ➡ Looking forward, we see the most organic growth for CDMOs to come from cell/gene therapy, with investment/M&A in the space increasing and the development pipeline strengthening ------------------------------------------------------------------------------------ Ready to leverage strategic intelligence to drive your CDMO growth strategy? We offer competitive intelligence monitoring services in key therapeutic areas with earnings call analyses, conference highlights, pipeline asset review, and strategic recommendation to make you stay ahead of the curve. Let us know your perspectives & challenges, and we will get you covered. Write us at bhabesh.panigrahi@eos-intelligence.com #genetherapy #cellandgenetherapy #pharmaceuticals #consulting #marketresearch #innovation #biopharma #biotech #future #growth #fda #pipeline #pharmamanufacturing #cmo #cdmo #biopharmaceuticals #eosintelligence #perspectives #strategy #intelligence #leadership Kemwell Biopharma WuXi Biologics Catalent Pharma Solutions Samsung Biologics Lonza Patheon MolMed now part of AGC Biologics BioNTech SE

Thoughts on this? >> Cencora's Lung-I Cheng: 'Cell and gene is becoming a very competitive space' - BioPharma-Reporter.com >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #competitivemarketing

Across the pharmaceutical industry, chemistry and biologics are converging to drive even greater innovation. 🧪 As these two disciplines come together, there is huge potential for revolutionizing drug development to help bring innovative treatments such as antibody-drug conjugates (ADCs), vaccines, and gene and cell therapies (GCTs) to market and change patients’ lives. 💉 Harnessing this power will require an increasingly in-depth understanding of the interplay between biology and chemistry to further advancements in drug design, development, and manufacturing. In the latest article with Specialty Chemistry Magazine, our expert Tom Wilson, Contract Manufacturing Lead at Pfizer CentreOne examines the changes biotechs need to make to realize the full potential of their biologics in the future. Read more below 👇 https://lnkd.in/eynRjZ2m #DrugDevelopment #CDMO #Biologics

Introducing the OmniCHO™ Transient Expression Kit, designed to revolutionize preclinical drug development by delivering scalable, high-yield protein production. With yields of over 1 g/L within 5 days or 2g/L in 10-12 days and a cost reduction of up to 30-fold per mg compared to traditional kits, OmniCHO empowers rapid, cost-efficient therapeutic development. Ideal for producing antibodies and hard-to-express proteins, this platform offers a game-changing solution for accelerating research timelines and time to IND. Explore the future of CHO-based expression with Celltheon!" https://lnkd.in/gnvY39Q2 #OmniCHO #Bioprocessing #Celltheon #ProteinProduction #BiotechInnovation

The integration of advanced methodologies in perfusion bioreactors is transforming the biopharmaceutical manufacturing landscape. New scale-down tools, such as quasi-perfusion microwell plates (MWP) and mini bioreactors (MBR), have shown remarkable efficiency in optimizing media for culturing mammalian cells. These tools enable high cell densities and increased productivity while minimizing costs and resource usage. For example, blending glucose-rich supplements with perfusion-specific base media led to an eight-fold increase in monoclonal antibody (mAb) titre compared to traditional fed-batch media. This innovation allows for higher yields and volumetric productivity, crucial for cost-effective biopharmaceutical production. Additionally, the combination of CRISPR gene editing and AI-enhanced methodologies is pioneering new paths in the treatment of cancer, particularly through synthetic lethality approaches. By focusing on loss-of-function mutations, which account for over half of genetic alterations causing cancer, researchers aim to fill significant gaps in available therapies. The development of high-throughput, small-scale experimental tools like the MWP not only accelerates media optimization but also reduces the environmental and financial burden of process development. This represents a significant leap towards more efficient and scalable production methods, ensuring that groundbreaking treatments can be brought to market more rapidly and affordably. #Biopharmaceuticals #PerfusionBioreactors #CRISPR #SyntheticLethality #PrecisionMedicine #CancerTreatment #Biotechnology #AIinHealthcare #HighThroughputScreening https://lnkd.in/g3TpPeSG

By 2027, biologics sales are projected to exceed those of small-molecule drugs, creating new opportunities for aseptic manufacturing. Unlike traditional medicines, biologics such as gene therapies lose potency under terminal sterilization, necessitating stringent aseptic processes to ensure safety and efficacy. The increased manual handling in gene therapy production emphasizes the need for robust aseptic controls, with closed systems and single-use technologies playing a pivotal role in advancing scalable manufacturing. As healthcare moves towards personalized treatments, biopharmaceutical manufacturing is transitioning from high-volume stainless steel bioreactors and single-product production to smaller, adaptable, multi-product facilities that can better accommodate tailored therapies. The future of biologic medications depends on scaling aseptic processes efficiently and economically, with modular facilities and closed processing providing opportunities to minimize contamination risks and enhance flexibility. At Helmchron, we leverage our extensive expertise in aseptic pharma manufacturing to ensure a seamless shift to innovative, multi-product manufacturing. 💬 Share your insights on the potential challenges facing aseptic processing for personalized therapies. ⬇️ #pharma #pharmaceuticals #CDMO @asepticmanufacturing #genetherapy